ArticleCell reports2019
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Abstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.
0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed.
- Podoplanin-positive extracellular vesicles in ovarian cancer: linking thrombosis, platelet crosstalk, and cancer stemness - a narrative review.Annals of medicine and surgery (2012) · 2026Article
- Aldehyde Detoxification in Cancer: Metabolic Guardians of the Genome.Biomolecules · 2026Review
- DCLK1 regulates stemness and IL-6/STAT3-dependent metastatic niche formation in chemoresistant ovarian cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer.Cancer letters · 2026Article
- A novel humanized immune stroma PDX cancer model for therapeutic studies.Cancer immunology, immunotherapy : CII · 2026Article
- Lys-ing the Resistance: Targeting Lysosomes to Overcome Chemoresistance in Ovarian Cancer.Current oncology reports · 2026Review
- Positive Feedback Loop of Histone Lactylation-Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Influences of RARγ on the Behavior of Normal and Cancer Stem Cells.International journal of molecular sciences · 2026Review
- Prognostic and Predictive Significance of Cancer Stem Cell Markers (ZIP-4 and ALDH1A1) in Ovarian Serous Carcinoma Patients: An Immunohistochemical Study.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Establishment of a Prognostic Necroptosis-Related lncRNA Signature in Ovarian Cancer.Combinatorial chemistry & high throughput screening · 2026Article
- Ovarian Cancer Stem Cells: Mechanisms of Progression and Therapeutic Strategies.Oncology research · 2026Review
- Integrative analysis of non-small cell lung cancer identifies Jumonji domain-containing 6/ETS homologous factor axis as a target to overcome radioresistance.Signal transduction and targeted therapy · 2025Article
- Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3.iScience · 2025Article
- Review
- Review
- A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities.Molecular cancer · 2025Review
- Deciphering the prognostic potential of a necroptosis-related gene signature in head and neck squamous cell carcinoma: a bioinformatic analysis.Translational cancer research · 2025Article
- The Significance of Aldehyde Dehydrogenase 1 in Cancers.International journal of molecular sciences · 2024Review
- Reactive oxygen species from non-thermal gas plasma (CAP): implication for targeting cancer stem cells.Cancer cell international · 2024Review
- The role of ALDH1A1 in glioblastoma proliferation and invasion.Chemico-biological interactions · 2024Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Ilana ChefetzDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Edward GrimleyDivision of Hematology-Oncology, Department of Internal Medicine, Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Kun YangDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Linda HongDivision of Gynecology-Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA.
Ekaterina V VinogradovaDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Radu SuciuDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Ilya KovalenkoDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.
David KarnakDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Cynthia A MorganDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Mikhail ChtcherbinineDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Cameron BuchmanDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Brandt HuddleVahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Scott BarrazaVahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Meredith MorganDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Kara A BernsteinDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Euisik YoonDepartment of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA.
David B LombardDepartment of Pathology and Institute of Gerontology, University of Michigan, Ann Arbor, MI, USA.
Andrea BildDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
Geeta MehtaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Iris RomeroDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Chun-Yi ChiangDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Charles LandenDepartment of Obstetrics and Gynecology, School of Medicine, University of Virginia, Charlottesville, VA, USA.
Benjamin CravattDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Thomas D HurleyDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Scott D LarsenVahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Ronald J BuckanovichDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA; Division of Hematology-Oncology, Department of Internal Medicine, Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; Magee-Womens Research Institute, Pittsburgh, PA, USA. Electronic address: buckanovichrj@mwri.magee.edu.
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2MVIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1MProject 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI CHANG, JEFFREY T · 2017 to 2021
$10.5MRegulation of one carbon metabolism and epigenetics by SIRT5R01GM101171 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2012 to 2021
$2.6MReplication fork dynamics and repair by Rad51 paralogues after DNA alkylationR01ES024872 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2015 to 2019
$2.4MActivation and Inhibition of Aldehyde Dehydrogenase 2R01AA018123 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI HURLEY, THOMAS D. · 2009 to 2013
$2.0MIsozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to ChemotherapyR01CA214567 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BUCKANOVICH, RONALD J, LARSEN, SCOTT D · 2017 to 2019
$1.8MUsing Microfluidic Single Cell Culture to Characterize Cancer Cell Asymmetric DivisionR01CA203810 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BUCKANOVICH, RONALD J, YOON, EUISIK · 2017 to 2020
$1.6MTargeting Ovarian Cancer Stem Cells Through Selective Inhibition of ALDH1A1R21CA198409 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI HURLEY, THOMAS D., MATEI, DANIELA E · 2015 to 2016
$373kNCI NIH HHS P30 CA014599NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA203810NCI NIH HHS R01 CA214567NCI NIH HHS R21 CA198409NCI NIH HHS U54 CA209978NIAAA NIH HHS R01 AA018123NIEHS NIH HHS R01 ES024872NIGMS NIH HHS R01 GM101171
Abstract
Ovarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer "stemness," and expression of the stem cell marker CD133. As such, ALDH activity has been proposed as a therapeutic target. Although it remains controversial which of the 19 ALDH family members drive chemotherapy resistance, ALDH1A family members have been primarily linked with chemotherapy resistant and stemness. We identified two ALDH1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially kills CD133
Indexed as
NecroptosisAC133 AntigenAldehyde Dehydrogenase 1 FamilyAnimalsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmEnzyme InhibitorsFemaleHumansMiceNeoplastic Stem CellsOvarian NeoplasmsOxidative PhosphorylationRetinal DehydrogenaseAC133 AntigenAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, mouseAntineoplastic AgentsEnzyme InhibitorsRetinal DehydrogenaseALDHCD133(+)cell deathCSCnecroptosisovarian cancerresistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.